Related Experiment Video

Updated: Jun 20, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Novel targets for therapeutic agents in small cell lung cancer

Patrick C Ma1, Ravi Salgia

  • 1Department of Medicine, Section of Hematology/Oncology, The University of Chicago Medical Center, Pritzker School of Medicine, Chicago, Illinois 60637, USA.

Journal of the National Comprehensive Cancer Network : JNCCN
|September 26, 2009
PubMed

Insights

Small cell lung cancer (SCLC) is aggressive and often metastasizes. Novel therapeutics targeting molecular pathways, particularly receptor tyrosine kinases (RTKs), offer new hope for improved patient outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Small cell lung cancer (SCLC) exhibits aggressive behavior and frequent distant metastasis.
  • SCLC patients often experience initial chemotherapy response followed by inevitable relapse within two years.
  • The poor prognosis and unique biology of SCLC highlight the need for novel therapeutic strategies.

Purpose of the Study:

  • To review current insights into novel molecular targets for SCLC treatment.
  • To discuss cellular signal transduction pathways relevant to SCLC.
  • To emphasize the role of receptor tyrosine kinases (RTKs) in SCLC therapeutic inhibition.

Main Methods:

  • Literature review of novel molecular targets in SCLC.
  • Analysis of cellular signal transduction pathways in SCLC.
  • Focus on receptor tyrosine kinases (RTKs) and their inhibitors.

Main Results:

  • Identified novel molecular targets in SCLC.
  • Discussed the involvement of cellular signaling in SCLC.
  • Highlighted receptor tyrosine kinases (RTKs) as key targets for therapeutic intervention.

Conclusions:

  • Novel therapeutics targeting molecular pathways, especially RTKs, hold promise for SCLC.
  • Small molecule inhibitors of RTKs like c-Kit, c-Met, and VEGF-R are under development.
  • Further clinical trials are anticipated to evaluate the efficacy of these novel SCLC treatments.

More Related Videos

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...